drugset / Trial / NCT07509086
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.
Timeline
- Start
- 2025-12-29
- Primary completion
- 2028-07-15
- Completion
- 2029-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IL-15-armored CAR-T cells | Cell therapy | 1e+06 cells | — |
| Subject | IL-15-armored CAR-T cells | Cell therapy | 1.5e+06 cells | — |
| Subject | IL-15-armored CAR-T cells | Cell therapy | 2e+06 cells | — |
| Subject | IL-15-armored CAR-T cells | Cell therapy | 3e+06 cells | — |